Foxy-5 (TFA)

Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2][3].

Product Specifications

UNSPSC

12352209

Target

Wnt

Type

Peptides

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/foxy-5-tfa.html

Purity

99.17

Solubility

DMSO : ≥ 100 mg/mL|H2O : 3.33 mg/mL (ultrasonic)

Smiles

O=C([C@H](CS)NC(CNC([C@H](CC(O)=O)NC([C@@H](NC=O)CCSC)=O)=O)=O)N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC(C)C)=O.OC(C(F)(F)F)=O

Molecular Formula

C28H43F3N6O14S2

Molecular Weight

808.80

References & Citations

[1]Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14 (20) :6556-63.|[2]Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39 (4) :1719-1728.|[3]Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12 (9) :e0184418.